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The large size of conventional antibodies impedes tissue penetration and renal elimination, resulting in suboptimal
in vivo targeting. Here we assess the utility of nanobodies and nanobody-Fc-fusion proteins as alternatives to
monoclonal antibodies as theranostics, using T cell ADP–ribosyltransferase 2 (ART2) as a model antigen for speciﬁc
targeting of lymph nodes. ART2-speciﬁc monovalent nanobody s +16a (17 kDa), a bivalent Fc-fusion protein of
s + 16a (s + 16-mFc, 82 kDa), and conventional antibody Nika102 (150 kDa) were labeled with AlexaFluor680. In vitro
binding and inhibitory properties of the three AF680 conjugates were assessed by ﬂow cytometry. For in vivo
imaging experiments, AF680 conjugates were intravenously injected in mice lacking (KO) or overexpressing (TG)
ART2. We monitored circulating and excreted AF680 conjugates in plasma and urine and performed in vivo
near-infrared ﬂuorescence imaging. Nanobody s + 16a680 and s + 16mFc680 labeled and inhibited ART2 on T cells in
lymph nodes within 10min. In contrast, mAb Nika102680 required 2h for maximal labeling without inhibition of
ART2. In vivo imaging revealed speciﬁc labeling of ART2-positive lymph nodes but not of ART2-negative lymph
nodes with all AF680 conjugates. Even though bivalent s + 16mFc680 showed the highest labeling efﬁciency
in vitro, the best lymph node imaging in vivo was achieved with monovalent nanobody s + 16a680, since renal
elimination of unbound s + 16a680 signiﬁcantly reduced background signals. Our results indicate that small
single-domain nanobodies are best suited for short-term uses, such as noninvasive imaging, whereas larger
nanobody-Fc-fusion proteins are better suited for long-term uses, such as therapy of inﬂammation and tumors.
Copyright © 2014 John Wiley & Sons, Ltd.
Additional supporting information may be found in the online version of this article at the publisher’s web site.
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1. INTRODUCTION
An important endeavor in immunobiology is to develop imaging
agents that can be used as therapeutic drugs, a concept termed
‘theranostics’ (1). Monoclonal antibodies are increasingly used
for therapy and in vivo imaging. However, the use of conven-
tional antibodies for speciﬁc noninvasive in vivo imaging is
limited owing the relatively large size, which impedes tissue pen-
etration and renal elimination (2). Both contribute to suboptimal
imaging conditions with low target-to-background ratios (3).
Moreover, clinical translation of molecular imaging techniques
will require imaging agents with the lowest possible likelihood
of toxicity and immunogenicity. One strategy for minimizing
these risks is to remove unbound material from the body via
renal excretion (4,5).
Nanobodies are small single-domain antigen binding frag-
ments derived from heavy-chain antibodies that are devoid of
light chains and occur naturally in camelidae (6,7). With a size of
about 13–17 kDa these nanobodies are 10 times smaller than
conventional antibodies (150 kDa). Recently, such nanobodies
have been shown to enable speciﬁc in vivo molecular imaging
of tumors, inﬂammation and the biodistribution of speciﬁc
immune cells (8–13). To the best of our knowledge, there is no de-
scription of nanobodies that can be used for in vivo near-infrared
ﬂuorescence (NIRF) imaging of immune cells and simultaneous
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modulation of immune cell function, for example, by inhibition of
a speciﬁc cell surface enzyme.
Here, we report the use of ADP-ribosyltransferase 2 (ART2) as a
model antigen to assess the utility of immunomodulating
nanobodies vs conventional antibodies as theranostic tools.
Toxin-related ART2 is an ecto-enzyme expressed on murine T
cells that catalyzes the transfer of ADP-ribose from NAD+ onto
target proteins on the cell surface, which induces apoptosis of
T cells, leading to selective depletion of T cell subsets (14–16).
Activity of ART2 can be monitored with the Nicotinamide
adenine dinucleotide (NAD)-analog etheno-NAD as substrate
and the ethenoadenosine-speciﬁc monoclonal antibody 1G4
to detect etheno-ADP-ribosylated proteins on the cell surface
(16–18). Recent studies revealed that the activity of ART2 and
ART2-mediated selective depletion of T cell subsets can be
inhibited by a blocking single-domain nanobody (s + 16a)
in vitro and in vivo (14,19). Moreover, a reformatted nanobody-
Fc-fusion protein (s + 16mFc) has been shown to mediate long-
term in vivo inhibition of ART2 activity and thereby to retard
development of autoimmune diabetes in a mouse model (20).
A single nanobody-based probe for noninvasive imaging and
simultaneous immunomodulation would be a desirable tool for
experimental as well as for clinical applications. In our study, the
recently developed ART2-speciﬁc monovalent nanobody s + 16a
(17 kDa) and the bivalent s + 16mFc-fusion protein (82 kDa) were
compared with the conventional monoclonal antibody Nika102
(150 kDa) for their capacity to inhibit and noninvasively image
ART2 on T cells using near-infrared-ﬂuorescence imaging in vivo.
2. RESULTS
2.1. Labeling and Inhibition of ART2 in vitro
Nanobody, nanobody-Fc-fusion protein and conventional
antibody were conjugated with AlexaFluor680 (Fig. 1). Flow
cytometry revealed speciﬁc binding of s + 16a680, s + 16mFc680
and Nika102680 to ART2 on T cells of BALB/c wild-type (WT) mice
and of transgenic mice overexpressing ART2 (TG), but not of
ART2-deﬁcient (KO) mice (Fig. 2). The results showed an
intermediate level of ART2 on WT T cells and a high level on
most, but not all, TG T cells. The monovalent single domain
nanobody s + 16a680 stained T cells slightly less efﬁciently than
the bivalent Fc-fusion protein s + 16mFc680 and the conventional
antibody Nika102680. Concomitant monitoring of the enzymatic
activity of ART2 with AlexaFluor488-conjugated mAb 1G4 (17)
revealed an almost complete inhibition of the enzymatic activity
of ART2 on T cells by s + 16a680 and s + 16mFc680, but only a
slight reduction by mAb Nika102680 (Fig. 2b). Control cells from
ART2-deﬁcient mice (21) did not show any detectable ART
activity, consistent with the lack of ART2 expression on these
cells (Fig. 2a, b).
To test the validity of the planned in vivo NIRF-imaging
experiments we determined the correlation of ART2 staining with
ﬂow cytometry and NIRF-imaging (Supporting Information, Fig. 1).
Regarding ART2-transfected cells, both techniques showed similar
dose-dependent labeling and saturating levels for each of the
AF680 conjugates. The two techniques showed a strong correlation
(r=0.975). Untransfected cells did not show any detectable signal
with Fluorescence activated cell sorting (FACS) or NIRF imaging.
2.2. Labeling and Inhibition of ART2 in vivo
T cells from lymph nodes were puriﬁed at different time points
after injection of 50 mg s + 16a680, s + 16mFc680 or Nika102680
(corresponding approximately to 3000, 600 and 300 pmol,
respectively) and analyzed by ﬂow cytometry for ART2-labeling
efﬁciency. For analysis of ART2-inhibition, T cells were incubated
with or without 10mM etheno-NAD and stained with the etheno-
adenosine speciﬁc antibody 1G4. Results of ex vivo FACS analyses
revealed that the smaller constructs s + 16a680 and s + 16mFc680
reached maximal labeling of ART2 on lymph node cells within
10min, whereas the larger mAb Nika102680 reached maximal
labeling of ART2 only after 2 h (Fig. 3a). Labeling with the
bivalent s + 16mFc680 and Nika102680 was constant for 12 h,
whereas labeling with monovalent s + 16a680 declined after 2 h.
Consistently, s + 16a680 and s + 16mFc680 showed an inhibition
of >90% of ART2-activity within 1–2 h (Fig. 3b). Mice injected
with s + 16mFc680 showed persistent inhibition of ART2-activity
for 12 h (>90%), whereas inhibition by s + 16a680 declined to
20% at 12 h after injection. In contrast, mAb Nika102680 showed
little if any inhibition of ART2-activity. Serum analyses revealed a
continuous decline of free s + 16a680 with an apparent serum
half-life of 1–2 h, whereas the larger fusion protein s + 16mFc680
and mAb Nika102680 showed little if any loss from circulation
for 12 h (Fig. 3c).
2.3. Serum and Urine Analyses
We performed comparative titration analyses to optimize the
concentration of the AF680 conjugates for in vivo imaging
experiments (Supporting Information, Fig. 2). At 2 h post
injection of the highest antibody dose (50 mg), serum samples
from both ART2-TG and ART2-KO mice showed high levels of
unbound circulating s + 16Fc680 and Nika102680, but little if any
unbound s + 16680 (Supporting Information, Fig. 2a, c). Urine
analyses revealed high levels of s + 16a680, but little if any
Figure 1. ART2-speciﬁc AF680 conjugates. (a) Scheme of nanobody s + 16a, nanobody-Fc-fusion protein s + 16mFc, and mAb Nika102. (b) The deep,
NAD+-binding active site crevice of ART2 is symbolized by the mouth of a ‘Pacman’. Both, s + 16a and s + 16mFc block the active site of ART2. Conven-
tional mAb Nika102 binds outside the active site and does not inhibit ART2 activity. (c) Coomassie stained gel overlaid by a corresponding near-infrared
ﬂuorescence (NIRF)-image of unconjugated s + 16a, s + 16mFc, and Nika102 (lanes 1, 3 and 5) and respective AF680 conjugates (lanes 2, 4 and 6).
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s + 16mFc680 and mAb Nika102680 (Supporting Information,
Fig. 2b, d). At lower doses (5 mg, 0.5 mg), unbound s + 16-Fc and
Nika102 were detectable in serum samples of ART2-KO mice,
but not in ART2-TG mice.
2.4. In vivo NIRF Imaging Experiments
In order to reduce background signals by unbound circulating
antibody conjugates, we used 50mg of s + 16a680, 5mg of
s + 16mFc680 and 10mg of Nika102680 (corresponding to 3000,
60 and 60 pmol or 5 1014, 8 1013 6 1014 ﬂuorescent dyes
per animal, respectively) in these experiments, using the results
shown above for guidance. Fluorescence of cervical and axillary
lymph nodes was visible in ART2-TGmice after injection of all three
conjugates (Fig. 4a). While s + 16mFc680 and Nika102680 showed
strong background ﬂuorescence, there was no background signal
in the case of s + 16a680. The clearest images showing high ﬂuores-
cence of lymph nodes were obtained 2h post injection of
s + 16a680 and, in case of the mAb Nika102680, only after 24 h.
The Fc-fusion protein s + 16mFc680 showed detectable lymph node
ﬂuorescence, albeit only slightly above background. Of note, at
24h after injection of the fusion protein s + 16mFc680 and mAb
Nika102680, ART2-TG mice showed less diffusely distributed
ﬂuorescence than ART2-KO mice. At this time point, none of the
mice injected with the s + 16a680 showed any detectable back-
ground signals.
Semiquantitative analyses of ﬂuorescence intensities of lymph
node regions over 24 h conﬁrmed rapid labeling by s + 16a680
with a maximal signal 1 h after injection (Fig. 4b). In ART2-KO
mice this was followed by a rapid decline in signal intensity.
The much slower decline of signal intensity of lymph nodes in
ART2-TG mice injected with s + 16a680 resulted in high target-
to-background ratios from 2 to 24 h.
In contrast, injection of s + 16mFc680 and mAb Nika102680
yielded maximal lymph node ﬂuorescence only at 2–4 h after in-
jection with signal intensities remaining nearly constant
thereafter over 24 h. The lower lymph node signal intensities in
mice injected with s + 16mFc680 and mAb Nika102680 vs
s + 16a680 are consistent with the amounts of injected conjugates.
Labeling of TG lymph nodes was clear and distinguishable
Figure 2. Analyses of ART2-expression and activity. (a) Lymph node cells from ART2-knockout mice (KO), ART2-wild-type mice (WT) and from trans-
genic mice overexpressing ART2 (TG) were stained with the indicated AF680 conjugates and subjected to FACS analyses. Mean ﬂuorescence intensities
of T cells are plotted (solid histograms). Open histograms show isotype controls. (b) Parallel aliquots of cells were pre-incubated in the absence (solid
black histograms) or presence (solid gray histograms) of the indicated AF680 conjugates. Cells were then further incubated in the presence of etheno-
NAD before detection of etheno-ADP-ribosylated cell surface proteins with mAb 1G4. Control stainings were performed in the absence of etheno-NAD
(open histograms). Results are representative of three independent experiments.
Figure 3. Staining and inhibition of ART2 in vivo after injection of AF680 conjugates. Wild-typemice were injected intravenously with 50mg of s + 16a680,
s + 16mFc680 or Nika102680 and sacriﬁced at the indicated time points. (a) Lymph node cells were subjected to ﬂow cytometry to detect cell surface-
bound AF680 conjugates. (b) Parallel aliquots of cells were incubated with 10 mM etheno-NAD for 10 min, washed and stained with 1G4-mAb to monitor
ART2 enzyme activity. (c) Serumwas analyzed to monitor levels of circulating unbound AF680 conjugates. Results are representative of two independent
experiments.
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compared to KO lymph nodes for all AF680 conjugates at all
imaging time points. However, the difference in labeling intensity
of TG vs KO lymph nodes was far higher for s + 16a680 than for the
larger conjugates s + 16mFc680 and Nika102680 for the entire pe-
riod from 2 to 24 h.
2.5. Ex vivo NIRF Imaging Experiments
In order to evaluate whether and to what extent the diffuse ﬂuo-
rescence observed (stronger in ART2-KO than in ART2-TG mice) af-
ter injection of the larger AF680 conjugates is attributed to
unbound circulating antibodies, serum samples were analyzed
for the presence of free AF680 conjugates at the time of sacriﬁce
(Supporting Information, Fig. 3a, b). The results revealed higher
levels of unbound s+ 16mFc680 and mAb Nika102680 in ART2-KO
than in ART2-TG mice already 2 h after injection (Supporting Infor-
mation, Fig. 3 a). At 24h after injection, no detectable unbound
AF680 conjugates remained in ART2-TG mice, while ART2-KO mice
still showed high levels of unbound s+ 16mFc680 and Nika102680
(Supporting Information, Fig. 3 b). Concomitant analyses of urine
samples revealed that renal excretion of s + 16a680 is terminated
24h after injection (Supporting Information, Fig. 3, compare c
and d).
To further validate the in vivo NIRF-imaging data, harvested
lymph nodes were imaged ex vivo (Fig. 5). Ex vivo NIRF-imaging
of isolated lymph nodes (Fig. 5a) conﬁrmed speciﬁc labeling of
cervical and axillary lymph nodes in ART2-TG mice but not in
ART2-KO mice with all conjugates. Fluorescence intensities of
lymph nodes obtained from ART2-TG mice injected with
s + 16a680 were 5–13 times higher than those from mice injected
with s + 16mFc680 and Nika102680 (Fig. 5b, Table 1). The results
conﬁrm the decline of lymph node ﬂuorescence 24 h after
injection of s + 16a-AF680, whereas lymph node ﬂuorescence
from ART2-TG mice remained constant from 2 to 24 h after
injection of the larger AF680 conjugates (Fig. 5b, Table 1). At 2 h
after injection all three AF680 conjugates showed signiﬁcant
differences in lymph node signals from ART2-TG and ART2-KO
mice, whereas after 24 h only s + 16a680 and Nika102680 still
showed signiﬁcant differences.
Analyses of spleen, lung, liver, kidneys, stomach and
muscle tissue (Table 1) showed that signals from spleen re-
ﬂect those described above for lymph nodes with signiﬁcant
Figure 4. In vivo NIRF-imaging. (a) ART2-TG mice and ART2-KO mice were injected with buffer (control), 50 mg s + 16a680, 5 mg s + 16mFc680 or 10 mg
Nika102680. Groups of control and antibody-injected mice (2 and 24 h after injection) were then subjected to simultaneous NIRF imaging to obtain
visually comparable images. Arrowheads indicate cervical and axillary lymph nodes. (b) Radiant efﬁciencies of regions of interest of lymph nodes are
plotted as a function of time for control mice and mice injected with s + 16a680, s + 16mFc680 and Nika102680. Data are presented as means SD from four
independent experiments.
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differences in ﬂuorescence signals between ART2-TG and
ART2-KO mice after 2 h for all three AF680 conjugates. Lung,
liver and muscle showed signiﬁcant differences in ﬂuores-
cence only at 2 h after injection of s + 16a680. At 24 h after
injection of s + 16a680 and Nika102680, lung, liver, kidney,
stomach and muscle organs from ART2-TG vs ART2-KO mice
did not show any signiﬁcant differences in ﬂuorescence while
lymph nodes and spleen (Table 1) still showed signiﬁcant dif-
ferences. Highest signal intensity was observed in kidneys 2 h
after injection of s + 16a680.
Table 1. Ex vivo radiant efﬁciencies of individual organs. Radiant effects ( 1010) are presented as means  SD. Statistical analyses
were performed using one-way ANOVA and Bonferroni post tests. n.s., Not signiﬁcant. p-Values are given for results of organs from
ART2-transgenic (TG) vs ART2-knockout (KO) mice
Time point Construct Animals Lymph nodes Spleen Lung Liver Kidneys Stomach Muscle
2 h p.i. s + 16a TG 27.9  6.7 17.0  2.5 6.4  1.2 34.4  3.4 432.3  63.8 17.9  4.1 2.5  0.6
KO 2.8  1.0 1.2  0.2 2.9  0.6 13.6  3.3 406.0  20.4 13.4  4.6 1.0  0.2
p <0.001 <0.001 <0.01 <0.001 n.s. n.s. <0.05
s + 16mFc TG 2.11  0.4 5.8  1.3 2.3  0.2 8.7  1.7 3.0  0.4 19.0  10.2 0.6  0.1
KO 0.8  0.1 1.2  0.1 1.6  0.1 7.2  1.0 2.4  0.2 4.0  0.3 0.7  0.4
p <0.001 <0.001 <0.01 n.s. n.s. n.s. n.s.
Nika102 TG 4.9  0.9 11.6  2.1 2.9  0.5 6.7  0.9 2.8  0.3 4.9  0.2 0.7  0.1
KO 1.2  0.1 1.4  0.1 3.8  0.4 10.4  2.1 4.0  0.5 4.9  0.3 0.9  0.1
p <0.01 <0.001 n.s. n.s. <0.05 n.s. n.s.
24 h p.i. s + 16a TG 15.0  2.3 6.1  1.0 1.8  0.3 3.2  0.3 10.6  2.4 5.3  0.8 0.7 0.1
KO 0.9  0.2 1.0  0.1 1.0  0.1 2.5  0.5 12.4  7.1 4.4  1.1 0.9  0.1
p <0.05 <0.05 n.s. n.s. n.s. n.s. n.s.
s + 16mFc TG 1.5  0.1 1.5  0.1 1.1  0.1 1.7  0.1 1.3  0.1 3.1  0.2 0.6  0.4
KO 1.0  0.1 0.9  0.1 1.6  0.2 3.5  0.7 1.9  0.2 4.7  0.7 0.7  0.3
p n.s. n.s. n.s. n.s. n.s. n.s. n.s.
Nika102 TG 3.9  0.7 5.5  0.7 1.3  0.1 1.7  0.1 1.4  0.1 2.7  0.2 0.6  0.1
KO 1.0  0.1 0.8  0.1 1.7  0.1 2.9  0.4 2.0  0.1 3.7  0.5 0.7  0.1
p <0.01 <0.01 n.s. n.s. n.s. n.s. n.s.
Figure 5. Ex vivo NIRF-imaging. (a) In order to quantitate lymph node associated ﬂuorescence in the absence of potentially confounding signals from
other tissues, lymph nodes (four axillary, two cervical and two inguinal) were dissected and pooled for direct NIRF-imaging. (b) Radiant efﬁciencies of
pooled lymph nodes are presented as means  SD from four independent experiments.
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3. DISCUSSION
In this study we report that simultaneous immunomodulation
and molecular imaging of T cells in vivo is achievable with
nanobodies. We used AF680-conjugated nanobodies to link
in vivo analyses by NIRF-imaging to ex vivo cell discriminating
assays by ﬂow cytometry. Our results demonstrate that monova-
lent s+16a680 and bivalent s+16mFc680 allow speciﬁc labeling
and inhibition of ART2 on T cells in vitro and in vivo. Even though
s+16mFc680 had the highest labeling efﬁciency in vitro, best
lymph node imaging in vivo was achieved with nanobody
s+16a680.
Speciﬁc labeling and imaging of cells with antibody conju-
gates directed against cell surface proteins is more challeng-
ing in vivo than in vitro. In vitro, conjugates have direct
access to their target cells and excess conjugates can readily
be removed by washing cells, yielding highly speciﬁc signals.
In vivo, conjugates need to cross barriers to reach their target
and unbound conjugates cause background signals until they
are removed from the system, for example, by renal or biliary
excretion (4,5). Our results indicate that the format of an an-
tibody conjugate governs its capacity to cross barriers and its
removal from the system, thereby profoundly affecting the
signal-to-background ratio and the optimal time point for
in vivo imaging.
An ideal targeted imaging agent should be able to pene-
trate the tissue, bind to speciﬁc cell surface antigens with
sufﬁcient afﬁnity to be retained in the target tissue and to
be cleared rapidly from the circulation to enable imaging in
a reasonable timescale (4,5). The rapid renal clearance of
s + 16a680 allowed us to use high concentrations of s + 16a
(50 mg or 3000 pmol) for in vivo NIRF-imaging experiments.
Comparative analyses of unbound conjugates in sera of
ART2KO and ART2TG mice allowed us to adjust the dosage
of bivalent s + 16mFc (5 mg or 60 pmol) and Nika102 (10 mg
or 60 pmol) conjugates to minimize levels of circulating anti-
bodies while still permitting good staining of lymph node
cells. To assess potential retention and metabolism of A680
conjugates by other organs, we performed region of interest
(ROI)-based quantiﬁcation from isolated organs. The results
revealed the highest signal in kidneys of mice 2 h after injec-
tion of s + 16a680, reﬂecting its renal excretion. Relatively high
signals were also observed in the spleen of ART2-transgenic
but not ART2-deﬁcient mice, consistent with the high content
of ART2 + T cells in the spleen. Signals from the liver in both
ART2-transgenic and ART2-deﬁcient mice could be due to
partial biliary elimination of AF680 conjugates and depleted
ﬂuorescent dye alone.
Our results are in accordance with previous studies, where
large, intact IgG antibody molecules with proven therapeutic
beneﬁt demonstrated limited utility in molecular imaging
owing to their slow clearance from circulation and tissues,
resulting in limited imaging contrast early after injection ow-
ing to a high background signal (2). This limitation can be
overcome by engineering antibody fragments (nanobodies)
that retain speciﬁc binding to the target antigen and at the
same time achieve fast blood clearance (9,12). It is conceiv-
able that imaging of ART2 + cells could be enhanced further
via dimerization of the nanobody, for example, by genetic
fusion or by disulﬁde linkages, which could enhance the avid-
ity of the probe for the target cells while at the same time
retaining elimination via the kidney. While these nanobodies
are ideally suited for imaging applications, their rapid renal
elimination limits their use for long-term therapeutic applica-
tions. To this end it would be desirable to increase their
apparent size to over 65 kDa to bypass kidney ﬁltration
(20,22). This can be achieved by various antibody engineering
strategies, such as, multimerization, fusion to other antibody
fragments or creation of bi-speciﬁc sdAbs, where one frag-
ment binds to a plasma carrier, such as albumin, to increase
the serum half-life (20,22–25). In accord with a previous study
(20), increasing the size by fusing the nanobody s + 16a to
the Fc domain of murine IgG1 improved and prolonged the
immunomodulatory properties in vivo. Inhibition of ART2 by
s + 16a protects regulatory T cells and iNKT cells from acute
NAD-induced cell death, whereas s + 16-Fc provides persistent
protection (14,20). It will be interesting to determine whether
the imaging techniques presented here will be theranostically
useful in models of acute inﬂammatory reactions such as
ConA-induced hepatits (26) and chronic inﬂammatory reac-
tions such as autoimmune diabetes (20).
An inherent technical limitation of NIRF-imaging is its low pene-
tration depth of 7–10mm owing to the absorbance and scattering
of light within biological tissues, resulting in lower sensitivities than
radioimmunological methods. Currently, these limitations are
addressed by the development of tomographic photo-acoustic
techniques allowing whole-body imaging of living mice (27). Be-
sides these limitations, NIRF-imaging provides several advantages
compared with other established pre-clinical imaging techniques,
such as computed tomography, magnetic resonance imaging,
and nuclear imaging (3,28). NIRF imaging is nonradioactive, highly
sensitive and relatively inexpensive, and the targeted probes are
comparatively easy to produce and store (29,30). Our results dem-
onstrated that NIRF-conjugated nanobodies have excellent prop-
erties for rapid preclinical optical imaging, which holds promise
for their future use as diagnostic tools in humans. Moreover, the
presented NIRF imaging techniques can be easily translated
to immuno-PET (Positron emission tomography) imaging by
radiolabeling of nanobodies. A recent PET study conﬁrmed faster
kinetics of radiolabeled nanobodies, allowing high contrast imag-
ing at early time points in comparison with radiolabeled conven-
tional monoclonal antibodies (12). Also the therapeutic aspects
of nanobodies have been highlighted in a recent study, where
radiolabeled nanobodies have been modiﬁed to extend their se-
rum half-life for optimized tumor therapy (25).
4. CONCLUSIONS
In this studywe illustrated NIRF-imagingwith nanobodies as a pow-
erful tool to detect immune cells in vivo and to simultaneouslymod-
ulate their function, highlighting the potential utility of nanobodies
as theranostics. The techniques described here may serve as a
model for other nanobody-based applications: small single domain
nanobodies are best suited for short-term uses, for example,
noninvasive imaging, whereas larger nanobody-Fc-fusion proteins
are better suited for long-term uses, for example, therapy of inﬂam-
mation and tumors.
5. EXPERIMENTAL
5.1. Chemicals, Cells and Mice
Etheno-NAD was obtained from Sigma-Aldrich. Phycoerythrin (PE)-
and Fluorescein isothiocyanate (FITC)-conjugated monoclonal
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antibodies were purchased from BD Pharmingen. Mouse monoclo-
nal antibody 1G4 (17) was conjugated to ﬂuorochrome Alexa488
as described previously (18). Untransfected and ART2-transfected
DC27.10 mouse lymphoma cells were cultured as described previ-
ously (16). BALB/c wild-type mice were obtained from the Jackson
Laboratory. Generation of ART2-deﬁcient mice and of transgenic
mice with overexpression of ART2 on T cells was described previ-
ously (21,31). Animal experiments were performed in accordance
with international guidelines on the ethical use of animals and were
approved by the local animal welfare commission.
5.2. Generation of ART2-Speciﬁc AF680 Conjugates
Generation and puriﬁcation of nanobody s + 16a (19), Fc-Fusion
protein s + 16mFc (20) and of monoclonal antibody Nika102 (32)
were described previously. ART2 speciﬁc probes were conjugated
by random reaction of primary amines to the succinimidyl ester
moiety of ﬂuorescent dye AlexaFluor-680 (AF680) (excitation
wavelength 679nm, emission wavelength 702nm). The numbers
of dye molecules per probe (0.3, 1.2 and 2.0 for s + 16a,
s + 16mFc and Nika102, respectively) were calculated according
to the manufacturer’s instructions (Molecular Probes; using molar
extinction coefﬁcients of 15 720, 51 170 and 203 000mol1 cm1,
respectively). Purity of antibody constructs before and after
conjugation to AF680 was assessed by SDS–PAGE size fraction-
ation and Coomassie Brilliant Blue gel stain (Fig 1). Binding
afﬁnities before and after conjugation as well as stability during
overnight incubation at 37 C in serum were assessed by serial
dilution of probes and ﬂow cytometry of DC27.10 cells. Binding
afﬁnities were 10 nM for Nika102, 5 nM for s + 16mFc and 40nM for
s + 16a. The results showed less than 10% reduction in labeling
efﬁciencies (mean ﬂuorescent intensity) upon conjugation and
overnight incubation in serum (results not shown).
5.3. Analysis of ART2 Expression and Enzymatic Activity
Mice were sacriﬁced by exposure to O2/CO2 followed by cervical
dislocation. Single-cell suspensions were prepared from lymph
nodes as described previously (31). For ART2-expression analyses,
cells (1 106) were stained with s + 16a, s + 16mFc and Nika102
AF680 conjugates (1mgml1) or AF680-control antibodies and
counterstained with PE-anti-CD3 for 20min at 4 C.
For ART2-activity analyses, cells (1 106) were pre-incubated in
the presence or absence of s + 16a, s + 16mFc and Nika102
AF680 conjugates (1mgml1) and then with or without 1mM
etheno-NAD for 20min at 4 C. Cells were washed twice and
stainedwith ethenoadenosine-speciﬁcmAbAlexa488-1G4 (1mgml1)
and counterstainedwith PE-anti-CD3. Cells werewashed twice and an-
alyzedbyﬂowcytometry on FACSCantoII. Dead cellswere excluded af-
ter staining with propidium iodide.
5.4. In vitro NIRF Imaging
An aliquot of 1.1 107 of untransfected or ART2-transfected
DC27.10 cells was incubated with different concentrations of
s + 16a680, s + 16mFc680 or Nika102680 for 30min at 4 C and
washed twice. An aliquot of 1 107 cells was sedimented on a
black 96-well plate (Nunc). Measurements were performed with a
whole-body small-animal NIRF imaging system (IVIS-Spectrum,
Caliper LifeSciences) using the 675nm band-pass (30 nm band-
width) ﬁlter for excitation and the 720, 740, 760 and 780nm
band-pass ﬁlters (20 nm bandwidth) for emission with a
512 512 pixel matrix size (15 15mm per pixel). Images were
analyzed semi-quantitatively by placing a ROI on individual wells.
Total radiant efﬁciency was calculated with Living Image 4.2
software (Caliper LifeSciences). An aliquot of 1 106 cells was
subjected to ﬂow cytometry for comparative analysis.
5.5. Analyses of AF680 Conjugates After Intravenous
Injection
An aliquot of 50mg of s + 16a680, s + 16mFc680 or Nika102680 (corre-
sponding to approximately 3000, 600 and 300 pmol, respectively)
in a volume of 200ml was administered intravenously into BALB/c
wild-type mice. T cells from lymph nodes were puriﬁed at different
time points after injection. For ﬂow cytometric analysis of
ART2-labeling efﬁciency, puriﬁed T cells were counterstained with
PE-anti-CD3. For analysis of ART2-inhibition by the different AF680
conjugates, T cells were incubated with or without 10mM etheno-
NAD, washed twice and stainedwith Alexa488-1G4 and PE-anti-CD3.
To measure blood clearance and renal excretion of AF680
conjugates, mice were sacriﬁced at different time points post
injection and blood and urine were collected. AF680 conjugates
were quantiﬁed by ﬂow cytometry using serum (1:100 dilution)
and urine (1:100 dilution) in a total volume of 100ml for labeling
1 106 ART2-expressing DC27.10 cells. For assessment of optimal
in vivo imaging conditions, AF680 conjugate concentrations of
0.5, 5 or 50mg of s + 16a680, s + 16mFc680and Nika102680 were
injected intravenously into wild-type mice. Animals were sacriﬁced
at different time points after injection and free abundant AF680
conjugates in serum and urinewere quantiﬁed as described above.
5.6. In vivo and ex vivo NIRF Imaging
ART2-deﬁcient and ART2-overexpressingmiceweremaintained on
an alfalfa-free diet for 2weeks prior to imaging experiments. The
day prior to the imaging experiment the ventral and lateral throat,
thorax and abdomen were depilated. For imaging experiments
50mg s+ 16a680, 5mg s+ 16mFc680 and 10mg of Nika102680 (corre-
sponding to approximately 3000, 60 and 60 pmol, respectively)
were administered intravenously in a volume of 200ml. Mice were
anesthetized with isoﬂuorane and positioned in the imaging
chamber, allowing for maintenance of gaseous anesthesia. NIRF-
imaging was performed before and 10min and 1, 2, 4, 6 and 24h
after injection. Imaging parameters were the same as for in vitro
imaging experiments. Radiant efﬁciency was estimated usingman-
ually drawn ROIs around the four brightest cervical and axillary
lymph node regions.
To validate the in vivo data, animals were sacriﬁced 2 or 24 h
after injection. NIRF imaging was performed of harvested lymph
nodes, spleens, lungs, livers, kidneys, muscle tissue and stomachs,
and radiant efﬁciencies were estimated.
5.7. Statistical Analysis
To assess the validity of semiquantitative results from NIRF imag-
ing, radiant efﬁciency measurements from NIRF imaging in vitro
experiments were compared with mean ﬂuorescence intensities
from ﬂow cytometry using Pearson’s correlation coefﬁcient. All
presented radiant efﬁciency data were calculated from four inde-
pendent experiments. A one-way ANOVA with a subsequent
Bonferroni post hoc analysis was used to determine signiﬁcant
differences between measurements obtained at different time
points and between measurements obtained from ART2-express-
ing and ART2-deﬁcient animals. A value of p< 0.05 indicates
statistical signiﬁcance. Data are presented as means standard
deviations. Statistical analysis was performed using Prism 4 for
Macintosh and Excel, Microsoft.
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